Abstract Details

Rimegepant is an orally administered small molecule CGRP receptor antagonist for the acute and preventive treatment of migraine.

Assess preference for and satisfaction with rimegepant as well as clinical global impression of change (CGI-C) over a 1-year open-label extension (OLE) phase in which rimegepant was used for both preventive and acute treatment of migraine.

This 1-year OLE phase of a 12-week, phase 2/3, randomized, double-blind, placebo-controlled study (NCT03732638) included adults aged ≥18 years with a history of 4 to 18 moderate to severe monthly migraine attacks. Subjects who completed 12 weeks of double-blind treatment with rimegepant 75 mg or placebo every other day could continue with open-label treatment with rimegepant 75 mg every other day for preventive treatment of migraine for 52 weeks. On nonscheduled dosing days, subjects could take rimegepant 75 mg up to once per day as needed for acute treatment of migraine. Exploratory objectives in this study included evaluating the effect of rimegepant on Preference of Medication (PoM), Satisfaction with Medication (SM), and CGI-C. The PoM, SM, and CGI-C were evaluated at Weeks 12 and 52 of the OLE phase (ie, overall study Weeks 24 and 64), and percentages (95% CIs) were calculated.

With long-term dosing of open-label rimegepant for both preventive treatment and acute treatment of migraine, the vast majority of subjects preferred rimegepant to prior migraine medications, were satisfied with rimegepant, and experienced clinical improvement.